Compare CTRI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRI | PHVS |
|---|---|---|
| Founded | 1909 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2024 | 2020 |
| Metric | CTRI | PHVS |
|---|---|---|
| Price | $21.53 | $33.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $28.17 | ★ $57.68 |
| AVG Volume (30 Days) | ★ 1.6M | 589.3K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,982,781,000.00 | N/A |
| Revenue This Year | $23.78 | N/A |
| Revenue Next Year | $12.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.10 | N/A |
| 52 Week Low | $18.60 | $21.02 |
| 52 Week High | $42.99 | $43.25 |
| Indicator | CTRI | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 60.84 | 59.31 |
| Support Level | $21.35 | $33.41 |
| Resistance Level | $28.61 | $36.36 |
| Average True Range (ATR) | 0.84 | 1.30 |
| MACD | 0.17 | 0.53 |
| Stochastic Oscillator | 87.80 | 97.38 |
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. Its reportable segments are: (i) U.S. Gas Utility Services (U.S. Gas); (ii) Canadian Utility Services (Canadian Operations); (iii) Union Electric Utility Services (Union Electric); and (iv) Non-Union Electric Utility Services (Non-Union Electric).
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.